Similar articles for PMID: 21816914

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
1999	5
2000	4
2001	11
2002	2
2003	5
2005	1
2006	7
2007	5
2008	2
2009	5
2010	5
2011	4
2012	10
2013	11
2014	12
2015	3
2016	1
2018	1
2020	1
2021	2
2022	0

Results by year

Page 1

Trastuzumab (herceptin).

Gemmete JJ, Mukherji SK. Gemmete JJ, et al. AJNR Am J Neuroradiol. 2011 Sep;32(8):1373-4. doi: 10.3174/ajnr.A2619. Epub 2011 Aug 4. AJNR Am J Neuroradiol. 2011. PMID: 21816914 Free PMC article.

[Trastuzumab (herceptin) for the medical treatment of breast cancer].

Bayoudh L, Afrit M, Daldoul O, Zarrad M, Boussen H. Bayoudh L, et al. Tunis Med. 2012 Jan;90(1):6-12. Tunis Med. 2012. PMID: 22311450 Free article. Review. French.

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

Shak S. Shak S. Semin Oncol. 1999 Aug;26(4 Suppl 12):71-7. Semin Oncol. 1999. PMID: 10482196 Review.

Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer.

Melichar B, Študentová H, Kalábová H, Vitásková D. Melichar B, et al. Immunotherapy. 2014;6(7):811-9. doi: 10.2217/imt.14.50. Immunotherapy. 2014. PMID: 25290414 Review.

New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.

Thill M. Thill M. Expert Rev Anticancer Ther. 2015 Mar;15(3):331-8. doi: 10.1586/14737140.2015.993318. Epub 2014 Dec 25. Expert Rev Anticancer Ther. 2015. PMID: 25539719 Review.

Her2-positive breast cancer: herceptin and beyond.

Dean-Colomb W, Esteva FJ. Dean-Colomb W, et al. Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18. Eur J Cancer. 2008. PMID: 19022660 Review.

[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].

Dank M. Dank M. Orv Hetil. 2001 Nov 18;142(46):2563-8. Orv Hetil. 2001. PMID: 11770175 Review. Hungarian.

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.

Haq B, Geyer CE. Haq B, et al. Womens Health (Lond). 2009 Mar;5(2):135-47. doi: 10.2217/17455057.5.2.135. Womens Health (Lond). 2009. PMID: 19245352 Free article. Review.

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.

Morris SR, Carey LA. Morris SR, et al. Oncology (Williston Park). 2006 Dec;20(14):1763-71; discussion 1771-2, 1774-6. Oncology (Williston Park). 2006. PMID: 17263127 Free article. Review.

Mechanism of action of anti-HER2 monoclonal antibodies.

Baselga J, Albanell J. Baselga J, et al. Ann Oncol. 2001;12 Suppl 1:S35-41. doi: 10.1093/annonc/12.suppl_1.s35. Ann Oncol. 2001. PMID: 11521720 Free article. Review.

92 results

Page of 10

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed